-
Roth Capital Affirms Palatin Technologies (PTN) at 'Buy'; Q1 Solid and Partnership Potential is Robust
-
Roth Capital Reaffirms Palatin Technologies (PTN) at 'Buy'; Focus Now on BMT Phase III Data
-
Buy Palatin Technologies (PTN) Ahead of Phase 3 BMT Data - Roth Capital
-
Palatin Technologies Announces Closing of $9.2 Million Financing
-
Palatin Technologies Announces $9.25 Million Financing
-
Palatin Tech (PTN) Management Entering Crunch Time on BMT; Roth Affirms at 'Buy'
-
Roth Capital Highlights Biotech Picks 'for the Turn' and Over the Long Haul (PTN) (LGND) (TGTX) (CLDX)
-
Palatin (PTN) 'Sitting Pretty' After Valeant/Sprout Deal - Roth Capital
-
Palatin's (PTN) BMT Thesis Improves with Recent Sprout Pharma News - Roth Capital (VRX)
-
Palatin Technologies' (PTN) BMT Has Advantages Over Flibanserin, Says Roth
-
Roth Capital Reiterates Buy Following Palatin Technologies (PTN) 'Positive' AdCom for Sprout's Flibanserin
-
Positive FDA Committee Vote on Flibanserin Bodes Well for Palatin's (PTN) Bremelanotide - Roth Capital
-
Palatin (PTN) Outpaces Q2 Ests on BMT Program Milestone; Roth Capital Affirms at 'Buy'
-
Roth Comments on Palatin's (PTN) BMT Agreement with European Partner; Reaffirms 'Buy' Rating
-
Roth Capital Positive on Palatin (PTN) Granting Bremelanotide Extension
-
Palatin Technologies (PTN) is Ready to Soar; Roth Reaffirms 'Buy' Rating
-
Roth Capital Starts Palatin Technologies (PTN) at Buy

